Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Case Study: Advanced Colorectal Cancer in a 56-year-old Female

Daniel Ahn, DO, MS, Assistant Professor of Medicine, Mayo Clinic, Arizona, discusses a case of advanced colorectal cancer in a 56-year-old female

Tags: Colorectal

Published: 20 November 2020

Recent Videos: Colorectal

video

Case Study: Advanced Colorectal Cancer in a 56-year-old Female

Daniel Ahn, DO, MS, Assistant Professor of Medicine, Mayo Clinic, Arizona, discusses a case of advanced colorectal cancer in a ...

video

Case Study: Second-Line Treatment of Colorectal Cancer in a 49-year-old Male

Sameh Mikhail, MD, Medical Oncologist, The Zangmeister Cancer Center, and Tanios Bekaii-Saab, MD, FACP, Consultant, Division of Hematology/Oncology, Department of ...

video

Case Study: Metastatic Colorectal Cancer in a 20-year-old Female

Namrata Vijayvergia, MD, Assistant Chief, Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses the treatment of metastatic colorectal cancer in ...

video

Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, shares design and outcomes from his study presented at ...

video

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, discusses what is next for Enhertu (trastuzumab deruxtecan) in ...

video

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients

Dr. Siena, Professor of Oncology, Università degli Studi di Milano, discusses the incidence of HER2+ patients amongst colorectal cancer patients ...

video

Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise

Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, explains the mechanism of action of Enhertu (trastuzumab deruxtecan) ...

video

Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinic, considers the emerging role of immunotherapy in the treatment of advanced colorectal ...

video

Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era

Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinic, discusses oral chemotherapy in the treatment of adjuvant and advanced colorectal cancer ...

video

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

Dr. Andre, Professor of Medical Oncology, Sorbonne University, discusses the evolution of I-O towards the first line treatment in colorectal ...

Related Videos

video-image

Case Study: Second-Line Treatment of Colorectal Cancer in a 49-year-old Male

video-image

Case Study: Metastatic Colorectal Cancer in a 20-year-old Female

video-image

Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

video-image

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

video-image

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients

video-image

Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise

video-image

Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment

video-image

Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era

video-image

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

video-image

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O

video-image

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

video-image

Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer

video-image

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

video-image

Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients

video-image

Howard Hochster, MD, shares his opinion of the "watch and wait" strategy as presented in the OPRA study

video-image

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers

video-image

Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study

video-image

Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC

video-image

Alan Venook, MD, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers

video-image

Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer

video-image

Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study

video-image

Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC

video-image

Alan Venook, MD, discusses uniqueness of MSI-High/mismatch repair deficient CRC patients

video-image

Tanios Bekaii-Saab, MD, FACP discusses how strategies for the treatment of colorectal cancer patients has changed at the Mayo Clinic as a result of COVID-19

video-image

Tanios Bekaii-Saab, MD, FACP, describes deintensification strategies in the management of advanced colorectal cancer patients brought to the forefront by COVID-19

video-image

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

video-image

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

video-image

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

video-image

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

video-image

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

video-image

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

video-image

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

video-image

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

video-image

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

video-image

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

video-image

Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy

video-image

Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients

video-image

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment

video-image

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time

video-image

Ryan Corcoran, explains cell free DNA and ways to test for it

video-image

Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma

video-image

Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC

video-image

Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment

video-image

Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies

video-image

Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC

video-image

Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age

video-image

Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients

video-image

David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients

video-image

Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC

video-image

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

video-image

Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer

video-image

Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients

video-image

Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017

video-image

Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer

video-image

Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Tanios Bekaii-Saab, MD, on how clinicians factor economics into therapeutic decision making

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

video-image

Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy

video-image

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

video-image

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.

video-image

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

video-image

Howard Hochster, MD on performance status importance in selecting treatment algorithms

video-image

Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors

video-image

Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients

video-image

Richard M. Goldberg, MD, FASCO on KRAS wild type or mutant in right or left-sided mCRC patients

video-image

Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment

video-image

Richard M. Goldberg, MD, FASCO discusses outcomes of the phase 3 CALGB/SWOG 80405 study

video-image

Bert O'Neil, MD on integrating regorafenib and trifluridine into later lines of mCRC treatment

video-image

Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients

video-image

Bert O'Neil, MD on the importance of choosing mCRC treatment based on primary tumor site

video-image

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

video-image

Alan Venook, MD, balancing economics with the efficacy outcomes seen in 80405

video-image

Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC

video-image

Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC

video-image

Alan Venook, MD on reliability of MSI-High predictor fpr response to nivolumab (Opdivo) in mCRC

video-image

Alan Venook, MD relates data presented in EPIC study relates to CALGB/SWOG 80405

video-image

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

video-image

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

video-image

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

video-image

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

video-image

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

video-image

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

video-image

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

video-image

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

video-image

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

video-image

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

video-image

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

video-image

Future of TAS-102 and regorafenib for patients with colorectal cancer